Moderna says the Food and Drug Administration has agreed to review its new mRNA-based flu shot after a highly public dispute about the vaccine’s trial design and initial refusal to file.
February 19, 2026
Moderna says the Food and Drug Administration has agreed to review its new mRNA-based flu shot after a highly public dispute about the vaccine’s trial design and initial refusal to file.